Perceptions of Rapid Antiretroviral Therapy Initiation Among Participants of The Netherlands Cohort Study on Acute HIV Infection.
Pien van Paassen, Maartje Dijkstra, Holly L Peay...
https://pubmed.ncbi.nlm.nih.gov/37791419/Actively Recruiting
Led by Prof. Jan Prins · Updated on 2023-02-15
183
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating the size, variability, and location of the viral reservoir in patients with acute HIV infection who start antiretroviral therapy immediately after diagnosis. The study aims to understand the immune responses related to achieving and maintaining post-treatment viral remission, a state where the virus remains controlled without ongoing treatment. This prospective cohort study also explores factors that influence viral latency and tests agents that might help maintain remission. Patients diagnosed with acute HIV infection are offered immediate standard first-line combination antiretroviral therapy cART. Participants are grouped based on their willingness to undergo additional sampling procedures Group 1 receives routine diagnostic tests only Group 2 adds semen sampling and leukapheresis Group 3 includes invasive tissue and cerebrospinal fluid sampling alongside routine tests. A control group with chronic infection is included for comparison. Throughout the study, participants undergo regular sampling of blood, semen, lymph nodes, gut tissue, and cerebrospinal fluid to analyze viral reservoirs and immune function. These samples are collected at various times including baseline, 24 weeks, and three years. The research monitors how these factors correlate with post-treatment viral remission over several years. The study combines routine clinical care visits with research procedures to minimize participant burden, and the total study duration is up to 10 years.
CONDITIONS
Netherlands Cohort Study on Acute HIV Infection
P
Pien van Paassen, MD
G
Godelieve de Bree, MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Prof. Jan Prins
Lead Sponsor
UMC Utrecht
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants diagnosed with acute HIV infection start combination anti-retroviral therapy (cART) and are monitored to analyze viral reservoir size and immune function. The extent of sampling varies by participant group, from routine diagnostic procedures to additional blood, semen, tissue, and cerebrospinal fluid sampling.
Routine clinical visits combined with additional sampling visits depending on group assignment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Pien van Paassen, Maartje Dijkstra, Holly L Peay...
https://pubmed.ncbi.nlm.nih.gov/37791419/Prof. Jan Prins
Lead Sponsor
UMC Utrecht
Collaborating Sponsor